
|Videos|November 10, 2018
Immunologic Biomarker Findings for mFOLFOX6 and Pembrolizumab in CRC
Author(s)Matthew Farren, PhD
Matthew Farren, PhD, post-doctoral fellow, Winship Cancer Institute, Emory University, discusses immunologic biomarker findings in a study of mFOLFOX6 plus pembrolizumab (Keytruda) in colorectal cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
3
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
4
Long-Term Outcomes Offer Reassurance on Quadruplet Use in Transplant-Ineligible NDMM
5
































